Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample.
Observations of impaired glucose regulation in schizophrenia are long-standing, although their pathological and etiological significance is uncertain. One approach to the issue that minimizes environmental variables (e.g., medication and diet) is to determine whether genes related to glucose regulation show genetic linkage to schizophrenia. We examined the potential role of glucose metabolism in schizophrenia through a genome scan of affection status in schizophrenia and an empirical method for deriving P-values. Data were utilized from the NIMH Genetics Initiative for Schizophrenia dataset, which comprises a total sample consisting of 71 pedigrees containing 218 nuclear families and 987 individuals. A genome scan with 459 markers spaced at an average of 10 cM intervals was conducted using the linkage analysis program Genehunter separately for European- and African-American groups. Enzymes that regulate glycolysis were identified and the genes regulating these enzymes were located through the Online Mendelian Inheritance in Man (OMIM) website. The focus in this study was on genes located near previously reported schizophrenia susceptibility regions. The genome-wide significance of these genes to schizophrenia was assessed using permutation testing. When results were adjusted for multiple testing within and across ethnic groups, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2; chromosome 1q32.2) achieved genome-wide significance (P = 0.04). In addition, hexokinase 3 (HK3; chromosome 5q35.3) was also suggestive of linkage (P = 0.09). For the European-American sample, PFKFB2 (1q32.2), hexokinase 3 (HK3; 5q35.3), and pyruvate kinase 3 (PK3; chromosome 15q23) achieved significance at the 0.05 level. None of the genes showed significance in the African-American sample. Our results provide further support for the view that genes that regulate glucose metabolism may also influence susceptibility to schizophrenia. More generally, they support the view that relationships between glucose dysregulation and schizophrenia are inherent to the disorder, and are not merely epiphenomena related to medication or other treatment factors.
Stone
William S
WS
Harvard Medical School Department of Psychiatry at Massachusetts Mental Health Center, Boston, Massachusetts 02115, USA. william_stone@hms.harvard.edu
Faraone
Stephen V
SV
Su
Jessica
J
Tarbox
Sarah I
SI
Van Eerdewegh
Paul
P
Tsuang
Ming T
MT
D001741:Black or African American / Q000235:genetics; D002874:Chromosome Mapping; D004798:Enzymes / Q000235:genetics*; D005260:Female; D008040:Genetic Linkage; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005838:Genotype; D006019:Glycolysis; D006593:Hexokinase / Q000235:genetics; D006801:Humans; D008126:Lod Score; D008297:Male; D009679:Nuclear Family; D010375:Pedigree; D010732:Phosphofructokinase-1 / Q000235:genetics; D025481:Phosphofructokinase-2 / Q000235:genetics; D011770:Pyruvate Kinase / Q000235:genetics; D012559:Schizophrenia / Q000208:ethnology / Q000235:genetics* / Q000473:pathology; D044465:White People / Q000235:genetics
D004798:Enzymes; C472074:HK1 protein, human; D006593:Hexokinase; D025481:Phosphofructokinase-2; D010732:Phosphofructokinase-1; D011770:Pyruvate Kinase